Lupin to develop inhalers with near-zero global warming potential propellants

Lupin's R&D teams are working on products with a near-zero global warming potential propellant

MRP of anti-cancer drugs to come down due to custom duty exemption and GST rate reduction

This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty

Prime Minister launches expansion of health coverage for citizens of and above 70 years

Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age

Aptar bags contract to advance novel sterilization technology for medical devices

ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure

Lupin appoints Claus Jepsen as President, Global Specialty

Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test

Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI

PM Modi inaugurates Rs. 110 crore R Jhunjhunwala Sankara Eye Hospital in Varanasi

Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension

Granules India receives ANDA approval for Bupropion Hydrochloride ER Tablets

Granules now has a total of 67 ANDA approvals from the USFDA

Long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years

Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years